Figure 4From: Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine Survival from on-study date as a function of TS gene expression. The median survival was 417 days in those with TS expression < median (n = 33), compared to 294 days in those with expression > median (n = 32). The Gehan-Breslow p value is shown.Back to article page